| Target Price | €13.87 |
| Price | €12.22 |
| Potential |
13.52%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Marimekko 2026 .
The average Marimekko target price is €13.87.
This is
13.52%
register free of charge
€16.80
37.48%
register free of charge
€13.64
11.58%
register free of charge
|
|
| A rating was issued by 13 analysts: 10 Analysts recommend Marimekko to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Marimekko stock has an average upside potential 2026 of
13.52%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 182.60 | 200.34 |
| 4.88% | 9.72% | |
| EBITDA Margin | 22.61% | 22.88% |
| 4.49% | 1.21% | |
| Net Margin | 13.35% | 13.77% |
| 1.54% | 3.18% |
7 Analysts have issued a sales forecast Marimekko 2025 . The average Marimekko sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Marimekko EBITDA forecast 2025. The average Marimekko EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Marimekko Analysts have issued a net profit forecast 2025. The average Marimekko net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.60 | 0.68 |
| 3.45% | 13.33% | |
| P/E | 17.98 | |
| EV/Sales | 2.58 |
7 Analysts have issued a Marimekko forecast for earnings per share. The average Marimekko EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


